Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Patients want bigger role in ICER assessments

Patient groups and medical product manufacturers are asking the Institute for Clinical and Economic Review (ICER) to implement major

Read the full 199 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE